Answers are grounded in this paper and cite their sources.
Conventional antidepressants remain not effective enough to treat depression, with only 30–40% of patients achieving full remission. This has intensified the call for a deeper understanding of depression’s biological mechanisms, moving beyond the traditional monoaminergic hypothesis. The cholinergic hypothesis, first proposed in the 1970s, has gained renewed interest due to the rapid antidepressant effects of scopolamine, a muscarinic receptor antagonist. Despite its potential, scopolamine’s side effects hinder clinical use. Recent research highlights dysregulation of glutamatergic neurotransmission in depression, and targeting metabotropic glutamate (mGlu) receptors presents a novel therapeutic strategy. Evidence suggests that mGlu 2 receptors play a critical role in the rapid antidepressant effect, and mGlu 2 receptor antagonists possess antidepressant-like potential in animal models of depression. Importantly, mGlu 2 antagonists such as LY341495 or the mGlu 2 negative allosteric modulator VU6001966, when coadministered with scopolamine, enhance scopolamine’s antidepressant efficacy while reducing cognitive side effects. Data indicate that ligands of other mGlu receptor subtypes, including group III mGlu receptors, may also enhance the therapeutic effects of scopolamine while avoiding undesirable effects. This review study underscores the urgent need for innovative approaches to depression treatment, emphasizing the importance of mGlu 2 as a promising target for future therapeutic development, especially as co-treatment with low doses of scopolamine. The mechanism related to the potentiation of the antidepressant effect of scopolamine by VU6001966, including activation of AMPA receptors and BDNF–TrkB signaling, is also discussed.
No takes yet. Share an insight, caveat, or question.
Babii et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: